Navigation Links
CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
Date:1/29/2009

BRANFORD, Conn., Jan. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), today reported its financial results for the fourth quarter and calendar year of 2008 and provided milestone and financial guidance for the first half of 2009.

During the three month period ended December 31, 2008, CuraGen utilized $3.8 million of cash and investments and ended the fourth quarter with $88 million of cash and investments. At December 31, 2008, CuraGen has outstanding $19 million of 4% convertible subordinated notes due February 2011 with a market value of approximately $15 million. For the quarter ended December 31, 2008, CuraGen reported total operating expenses of $4.1 million, compared to total operating expenses of $11.1 million during the same period in 2007. Included in fourth quarter operating expenses is approximately $0.5 million of restructuring charges for a reduction in work force undertaken in December 2008.

"We currently have $88 million of cash and investments on hand and an attractive Phase II development asset that shows activity in metastatic melanoma and promise in breast cancer." commented Dr. Timothy M. Shannon, President and Chief Executive Officer. "We are encouraged by the activity CR011-vcMMAE has demonstrated to date and we will be releasing additional data on our two ongoing trials in the second quarter of 2009" commented Dr. Shannon.

2009 Milestones and Financial Guidance

The following statements are based on CuraGen's current expectations. These statements are forward-looking and actual results may differ materially. Please see the note regarding Forward-Looking Statements in this release for a description of certain important risk factors that could cause actual results to differ and refer to CuraGen's periodic reports on file with the Securities and Exchange Commission for a more complete descrip
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CuraGen Reports Third Quarter 2008 Financial Results
2. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
3. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
4. CuraGen to Present at the BIO CEO & Investor Conference
5. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
6. CuraGen Corporation Receives Notification from NASDAQ
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
9. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
10. CuraGen Appoints Clinical Oncologist as VP of Medical Development
11. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 01, 2015 Spirax Sarco, the leader ... proud to announce that for the first time in ... winner of a Queen’s Award for Innovation – the ... and manufacture of a unique flowmeter. , The Spirax ... to traditional steam flow measurement. The device provides ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. ... in the development of biosimilar therapeutics including high ... the closing of its previously announced underwritten public ... at a public offering price of $15.50 per ... the underwriters of their option to purchase up ...
(Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative ... reactive skin while battling the weakening threat of ... cream is formulated with star ingredient GLYCOSEA, a ... in a complex of soothing minerals and trace ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3
... 2012  Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Paul Bisaro, Watson,s President and Chief Executive Officer, will ... at the Goldman Sachs Global Healthcare Conference 2012 on ... the Terranea Resort in Rancho Palos Verdes, California.  The ...
... 2012 TOKU-E Company ( http://www.toku-e.com ) ... faster dissolving dust-free grade (DF) Sodium Dodecyl Sulfate (SDS). ... dust particles is known to cause eye and skin ... chronic skin hypersensitivity, with some people being affected more ...
... SEATTLE, May 29, 2012 Cell Therapeutics, Inc. ("CTI") (Nasdaq ... an agreement to sell, subject to customary closing conditions, $40 ... and warrants to purchase shares of its common stock (and ... upon conversion of the Series 15 Convertible Preferred Stock and ...
Cached Biology Technology:Watson to Present at Goldman Sachs Global Healthcare Conference 2012 2TOKU-E Announces Safer and Faster Dissolving, Dust-Free Grade Sodium Dodecyl Sulfate (SDS) for Electrophoresis and Manufacturing Applications 2Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 2Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 3Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 4Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 5Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 6
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... fictitious storybook character Dr. Doolittle was known for ... professor of psychology at Rochester Institute of Technology, ... object discrimination in goldfish and echolocation in dolphins ... of animal perception and cognition. DeLong,s theories ...
... California, Davis, and BGI, the world,s largest genomic institute, ... will change the landscape of genomic sciences in California ... the areas of food security and human, animal and ... BGI sequencing facility for immediate use on the UC ...
... CAMDEN -- In this era of environmental consciousness, many ... is taking the term quite literally. Elizabeth Demaray, an ... sides of New York City skyscrapers to counteract the lack ... Skyscrapers Project" was featured as part of New York,s Art ...
Cached Biology News:Go fish! RIT psychology professor trains goldfish for object perception research 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 3Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... TYPE II Reacts with most of ... cell keratin of 86 and 58kD and ... keratin reactivity is found on human epidermal ... Immunogen: Human epidermal cells ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Biology Products: